YN001 + glucose

YN001 is an investigational recombinant biologic agent, specifically a monoclonal antibody, developed by Beijing Inno Medicine Co., Ltd. for the treatment of atherosclerotic cardiovascular disease (ASCVD) and associated conditions such as erectile dysfunction (ED) and cerebrovascular disease. The drug is administered via intravenous infusion, typically diluted in a 5% glucose solution. YN001 is designed to target the inflammatory and lipid-driven processes of atherosclerosis, with clinical studies evaluating its ability to reduce carotid artery intima-media thickness and improve vascular-related erectile function. It has progressed to Phase IIa clinical trials, demonstrating a safety and pharmacokinetic profile suitable for further development in patients with coronary and carotid atherosclerosis.